阿泰宁治疗肠易激综合征50例的疗效观察  

Efficacy of Ataining in the treatment of 50 cases with IBS

作　　者：聂昭华[1] 彭国球[2] 张敏[1] 张大为[1] 刘莉[1] 万阜昌 李洪福 崔云龙 聂艳孝[2] 郭翠英[1] 

机构地区：[1]解放军第261医院,北京100094 [2]解放军第304医院,北京100037 [3]北京天施康医药科技发展有限公司,北京100037 [4]青岛东海药业有限公司,山东青岛266400

出　　处：《中国微生态学杂志》2006年第6期441-443,共3页Chinese Journal of Microecology

基　　金：国家科技部创新基金项目(01C26211100765)

摘　　要：目的 观察和评价阿泰宁（含酪酸梭菌CGMCC NO.0313-1株）治疗肠易激综合征（IBS）的临床疗效.方法 对符合罗马Ⅱ诊断标准的IBS患者,用阿泰宁胶囊口服,1次3粒,1天2次,疗程14～21 d.治疗期间观察患者的症状变化、服药情况,治疗结束后评价药物的疗效.结果 50例IBS患者治疗后的腹泻或便秘等症状有显著的改善（P＜0.05）.治愈率为62%（31/50）,总有效率为94%（47/50）,治疗中未见不良反应或副作用.结论 阿泰宁是治疗IBS的一种安全有效的微生态药品,不但短期应用效果好,而且慢性腹泻或便秘患者可长期服用.Objective To observe and evaluate the efficacy of Ataining （containing Clostridiurn butyricum CGMCC NO. 0313-1 strain） in the treatment of IBS. Methods Patients with IBS were received orally a dose of three capsules of Ataining every time ,twice daily for 14-21 days. Altered of symptoms of patients and using drug condition has been observed consistently during the treatment period, and the efficacy of Ataining on the IBS had been evaluated in the treatment end. Results 50 patients had obviously improved （P〈0.05） in the symptoms （ such as diarrhea and constipation etc. ） after treatment. The cure rate of IBS was 62%, total effectiveness rate was 94%, and no adverse reactions or side effects were observed in all clinical trial. Conclusion Ataining was considered to be effective and safe probiotics in the treatment of IBS, and it suited for long-term use in patients with chronic diarrhea or chronic constipation.

关 键 词：阿泰宁 肠易激综合征 疗效 

分 类 号：R574.4[医药卫生—消化系统]